If you have treatment-resistant depression, you can be among the first in Wisconsin to start on Esketamine…
“This offers hope, in capital letters,”
— Dennis Charney, dean of the Icahn School of Medicine in New York
Esketamine, the first new drug based on ketamine, just gained FDA approval for patients with treatment resistant depression!
Going by the name Spravato, esketamine spray is basically half of the ketamine compound- one side of mirror image ketamine molecules. It works in the same way as IV ketamine, and we expect it will have similar effectiveness to the parent ketamine drug.
If it is almost the same, what’s the big deal?
Spravato is expected to be covered by most insurances in the coming months. When that happens, we will be sure to bring it to you.
To be among the first in Wisconsin to try Spravato, contact us below: